Given the dual activation of potent oncogenic pathways by RAS in MM, along with the high frequency of both KRAS and NRAS mutations in aggressive relapsed and refractory disease, effectively targeting RAS signaling represents a potential therapeutic approach for patients with tumors that have failed to respond to existing therapies. This evidence concerns the gene KRAS and Miyoshi myopathy.